nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—HPGDS—liver cancer	0.729	1	CbGaD
Dinoprostone—ABCC4—Sorafenib—liver cancer	0.0478	0.818	CbGbCtD
Dinoprostone—CYP1A2—Sorafenib—liver cancer	0.0106	0.181	CbGbCtD
Dinoprostone—Oedema genital—Epirubicin—liver cancer	0.00277	0.078	CcSEcCtD
Dinoprostone—Oedema genital—Doxorubicin—liver cancer	0.00257	0.0722	CcSEcCtD
Dinoprostone—Dinoprost Tromethamine—HPGDS—liver cancer	0.00228	1	CrCbGaD
Dinoprostone—Dehydration—Sorafenib—liver cancer	0.000686	0.0193	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Sorafenib—liver cancer	0.00056	0.0158	CcSEcCtD
Dinoprostone—Myocardial infarction—Sorafenib—liver cancer	0.000557	0.0157	CcSEcCtD
Dinoprostone—Laryngitis—Epirubicin—liver cancer	0.000521	0.0147	CcSEcCtD
Dinoprostone—Laryngitis—Doxorubicin—liver cancer	0.000482	0.0136	CcSEcCtD
Dinoprostone—Flushing—Sorafenib—liver cancer	0.000473	0.0133	CcSEcCtD
Dinoprostone—Angiopathy—Sorafenib—liver cancer	0.000463	0.013	CcSEcCtD
Dinoprostone—Immune system disorder—Sorafenib—liver cancer	0.000461	0.013	CcSEcCtD
Dinoprostone—Arrhythmia—Sorafenib—liver cancer	0.000456	0.0128	CcSEcCtD
Dinoprostone—Muscle spasms—Sorafenib—liver cancer	0.000427	0.012	CcSEcCtD
Dinoprostone—Skin discolouration—Epirubicin—liver cancer	0.000416	0.0117	CcSEcCtD
Dinoprostone—Syncope—Sorafenib—liver cancer	0.000398	0.0112	CcSEcCtD
Dinoprostone—Loss of consciousness—Sorafenib—liver cancer	0.00039	0.011	CcSEcCtD
Dinoprostone—Cough—Sorafenib—liver cancer	0.000387	0.0109	CcSEcCtD
Dinoprostone—Inflammation—Epirubicin—liver cancer	0.000387	0.0109	CcSEcCtD
Dinoprostone—Skin discolouration—Doxorubicin—liver cancer	0.000385	0.0108	CcSEcCtD
Dinoprostone—Hypertension—Sorafenib—liver cancer	0.000383	0.0108	CcSEcCtD
Dinoprostone—Arthralgia—Sorafenib—liver cancer	0.000378	0.0106	CcSEcCtD
Dinoprostone—Myalgia—Sorafenib—liver cancer	0.000378	0.0106	CcSEcCtD
Dinoprostone—Hiccups—Epirubicin—liver cancer	0.000375	0.0106	CcSEcCtD
Dinoprostone—Vaginal inflammation—Epirubicin—liver cancer	0.000375	0.0106	CcSEcCtD
Dinoprostone—Anaphylactic shock—Sorafenib—liver cancer	0.000362	0.0102	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—liver cancer	0.000358	0.0101	CcSEcCtD
Dinoprostone—Shock—Sorafenib—liver cancer	0.000357	0.01	CcSEcCtD
Dinoprostone—Vaginal infection—Epirubicin—liver cancer	0.000354	0.00997	CcSEcCtD
Dinoprostone—Vaginal inflammation—Doxorubicin—liver cancer	0.000347	0.00977	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—liver cancer	0.000347	0.00977	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Epirubicin—liver cancer	0.000345	0.0097	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00033	0.00929	CcSEcCtD
Dinoprostone—Hypertonia—Epirubicin—liver cancer	0.000329	0.00926	CcSEcCtD
Dinoprostone—Vaginal infection—Doxorubicin—liver cancer	0.000328	0.00923	CcSEcCtD
Dinoprostone—Dyspnoea—Sorafenib—liver cancer	0.000323	0.00909	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Doxorubicin—liver cancer	0.000319	0.00898	CcSEcCtD
Dinoprostone—Pain—Sorafenib—liver cancer	0.00031	0.00872	CcSEcCtD
Dinoprostone—Hypertonia—Doxorubicin—liver cancer	0.000304	0.00857	CcSEcCtD
Dinoprostone—Eye pain—Epirubicin—liver cancer	0.000302	0.00849	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Sorafenib—liver cancer	0.000296	0.00834	CcSEcCtD
Dinoprostone—Hot flush—Epirubicin—liver cancer	0.000291	0.0082	CcSEcCtD
Dinoprostone—Menopausal symptoms—Epirubicin—liver cancer	0.000289	0.00813	CcSEcCtD
Dinoprostone—Body temperature increased—Sorafenib—liver cancer	0.000286	0.00806	CcSEcCtD
Dinoprostone—Abdominal pain—Sorafenib—liver cancer	0.000286	0.00806	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Epirubicin—liver cancer	0.000282	0.00792	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—liver cancer	0.000279	0.00786	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—liver cancer	0.00027	0.00758	CcSEcCtD
Dinoprostone—Menopausal symptoms—Doxorubicin—liver cancer	0.000267	0.00752	CcSEcCtD
Dinoprostone—Hypersensitivity—Sorafenib—liver cancer	0.000267	0.00751	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00026	0.00733	CcSEcCtD
Dinoprostone—Asthenia—Sorafenib—liver cancer	0.00026	0.00732	CcSEcCtD
Dinoprostone—Cardiac arrest—Epirubicin—liver cancer	0.000259	0.00729	CcSEcCtD
Dinoprostone—Dehydration—Epirubicin—liver cancer	0.000253	0.00713	CcSEcCtD
Dinoprostone—Diarrhoea—Sorafenib—liver cancer	0.000248	0.00698	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—liver cancer	0.00024	0.00675	CcSEcCtD
Dinoprostone—Dizziness—Sorafenib—liver cancer	0.00024	0.00674	CcSEcCtD
Dinoprostone—Asthma—Epirubicin—liver cancer	0.000236	0.00663	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—liver cancer	0.000234	0.0066	CcSEcCtD
Dinoprostone—Vomiting—Sorafenib—liver cancer	0.00023	0.00648	CcSEcCtD
Dinoprostone—Rash—Sorafenib—liver cancer	0.000228	0.00643	CcSEcCtD
Dinoprostone—Dermatitis—Sorafenib—liver cancer	0.000228	0.00642	CcSEcCtD
Dinoprostone—Headache—Sorafenib—liver cancer	0.000227	0.00639	CcSEcCtD
Dinoprostone—Asthma—Doxorubicin—liver cancer	0.000218	0.00613	CcSEcCtD
Dinoprostone—Nausea—Sorafenib—liver cancer	0.000215	0.00606	CcSEcCtD
Dinoprostone—Pharyngitis—Epirubicin—liver cancer	0.000187	0.00526	CcSEcCtD
Dinoprostone—Flushing—Epirubicin—liver cancer	0.000175	0.00492	CcSEcCtD
Dinoprostone—Pharyngitis—Doxorubicin—liver cancer	0.000173	0.00487	CcSEcCtD
Dinoprostone—Angiopathy—Epirubicin—liver cancer	0.000171	0.00481	CcSEcCtD
Dinoprostone—Immune system disorder—Epirubicin—liver cancer	0.00017	0.00479	CcSEcCtD
Dinoprostone—Chills—Epirubicin—liver cancer	0.000169	0.00476	CcSEcCtD
Dinoprostone—Arrhythmia—Epirubicin—liver cancer	0.000168	0.00474	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—liver cancer	0.000162	0.00455	CcSEcCtD
Dinoprostone—Tension—Epirubicin—liver cancer	0.000161	0.00453	CcSEcCtD
Dinoprostone—Back pain—Epirubicin—liver cancer	0.000159	0.00447	CcSEcCtD
Dinoprostone—Angiopathy—Doxorubicin—liver cancer	0.000158	0.00445	CcSEcCtD
Dinoprostone—Muscle spasms—Epirubicin—liver cancer	0.000158	0.00444	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—liver cancer	0.000158	0.00443	CcSEcCtD
Dinoprostone—Chills—Doxorubicin—liver cancer	0.000157	0.0044	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—liver cancer	0.000156	0.00438	CcSEcCtD
Dinoprostone—Vision blurred—Epirubicin—liver cancer	0.000155	0.00435	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—liver cancer	0.000149	0.00419	CcSEcCtD
Dinoprostone—Syncope—Epirubicin—liver cancer	0.000147	0.00414	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—liver cancer	0.000147	0.00413	CcSEcCtD
Dinoprostone—Muscle spasms—Doxorubicin—liver cancer	0.000146	0.00411	CcSEcCtD
Dinoprostone—Loss of consciousness—Epirubicin—liver cancer	0.000144	0.00406	CcSEcCtD
Dinoprostone—Cough—Epirubicin—liver cancer	0.000143	0.00403	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—liver cancer	0.000143	0.00403	CcSEcCtD
Dinoprostone—Hypertension—Epirubicin—liver cancer	0.000142	0.00399	CcSEcCtD
Dinoprostone—Chest pain—Epirubicin—liver cancer	0.00014	0.00393	CcSEcCtD
Dinoprostone—Arthralgia—Epirubicin—liver cancer	0.00014	0.00393	CcSEcCtD
Dinoprostone—Myalgia—Epirubicin—liver cancer	0.00014	0.00393	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—liver cancer	0.000136	0.00383	CcSEcCtD
Dinoprostone—Anaphylactic shock—Epirubicin—liver cancer	0.000134	0.00377	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—liver cancer	0.000133	0.00375	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—liver cancer	0.000132	0.00373	CcSEcCtD
Dinoprostone—Shock—Epirubicin—liver cancer	0.000132	0.00371	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—liver cancer	0.000131	0.00369	CcSEcCtD
Dinoprostone—Tachycardia—Epirubicin—liver cancer	0.000131	0.00368	CcSEcCtD
Dinoprostone—Hyperhidrosis—Epirubicin—liver cancer	0.000129	0.00364	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—liver cancer	0.000129	0.00364	CcSEcCtD
Dinoprostone—Chest pain—Doxorubicin—liver cancer	0.000129	0.00364	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—liver cancer	0.000129	0.00364	CcSEcCtD
Dinoprostone—Hypotension—Epirubicin—liver cancer	0.000125	0.00352	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—liver cancer	0.000124	0.00349	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000122	0.00343	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—liver cancer	0.000122	0.00343	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—liver cancer	0.000121	0.0034	CcSEcCtD
Dinoprostone—Paraesthesia—Epirubicin—liver cancer	0.00012	0.00338	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—liver cancer	0.00012	0.00337	CcSEcCtD
Dinoprostone—Dyspnoea—Epirubicin—liver cancer	0.000119	0.00336	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—liver cancer	0.000116	0.00326	CcSEcCtD
Dinoprostone—Pain—Epirubicin—liver cancer	0.000115	0.00322	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000113	0.00318	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—liver cancer	0.000111	0.00313	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—liver cancer	0.00011	0.00311	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Epirubicin—liver cancer	0.00011	0.00308	CcSEcCtD
Dinoprostone—Pain—Doxorubicin—liver cancer	0.000106	0.00298	CcSEcCtD
Dinoprostone—Abdominal pain—Epirubicin—liver cancer	0.000106	0.00298	CcSEcCtD
Dinoprostone—Body temperature increased—Epirubicin—liver cancer	0.000106	0.00298	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000101	0.00285	CcSEcCtD
Dinoprostone—Hypersensitivity—Epirubicin—liver cancer	9.87e-05	0.00278	CcSEcCtD
Dinoprostone—Body temperature increased—Doxorubicin—liver cancer	9.8e-05	0.00276	CcSEcCtD
Dinoprostone—Abdominal pain—Doxorubicin—liver cancer	9.8e-05	0.00276	CcSEcCtD
Dinoprostone—Asthenia—Epirubicin—liver cancer	9.61e-05	0.0027	CcSEcCtD
Dinoprostone—Diarrhoea—Epirubicin—liver cancer	9.16e-05	0.00258	CcSEcCtD
Dinoprostone—Hypersensitivity—Doxorubicin—liver cancer	9.13e-05	0.00257	CcSEcCtD
Dinoprostone—Asthenia—Doxorubicin—liver cancer	8.89e-05	0.0025	CcSEcCtD
Dinoprostone—Dizziness—Epirubicin—liver cancer	8.86e-05	0.00249	CcSEcCtD
Dinoprostone—Vomiting—Epirubicin—liver cancer	8.52e-05	0.0024	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—liver cancer	8.48e-05	0.00239	CcSEcCtD
Dinoprostone—Rash—Epirubicin—liver cancer	8.44e-05	0.00238	CcSEcCtD
Dinoprostone—Dermatitis—Epirubicin—liver cancer	8.44e-05	0.00237	CcSEcCtD
Dinoprostone—Headache—Epirubicin—liver cancer	8.39e-05	0.00236	CcSEcCtD
Dinoprostone—Dizziness—Doxorubicin—liver cancer	8.19e-05	0.00231	CcSEcCtD
Dinoprostone—Nausea—Epirubicin—liver cancer	7.96e-05	0.00224	CcSEcCtD
Dinoprostone—Vomiting—Doxorubicin—liver cancer	7.88e-05	0.00222	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—liver cancer	7.81e-05	0.0022	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—liver cancer	7.81e-05	0.0022	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—liver cancer	7.76e-05	0.00218	CcSEcCtD
Dinoprostone—Nausea—Doxorubicin—liver cancer	7.36e-05	0.00207	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—STAT3—liver cancer	9.49e-06	5.41e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—GSTP1—liver cancer	9.47e-06	5.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—PIK3CA—liver cancer	9.43e-06	5.38e-05	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—PIK3CA—liver cancer	9.43e-06	5.38e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SERPINE1—liver cancer	9.41e-06	5.37e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SERPINE1—liver cancer	9.41e-06	5.37e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PPARG—liver cancer	9.41e-06	5.37e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—RAF1—liver cancer	9.39e-06	5.35e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—HMOX1—liver cancer	9.34e-06	5.33e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—KRAS—liver cancer	9.32e-06	5.32e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—KRAS—liver cancer	9.32e-06	5.32e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CYCS—liver cancer	9.31e-06	5.31e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CYP2E1—liver cancer	9.28e-06	5.29e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GGT1—liver cancer	9.14e-06	5.21e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GOT1—liver cancer	9.14e-06	5.21e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CYP1A1—liver cancer	9.13e-06	5.21e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—PIK3CA—liver cancer	9.12e-06	5.2e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CTNNB1—liver cancer	9.03e-06	5.15e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—HRAS—liver cancer	8.96e-06	5.11e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GSTP1—liver cancer	8.96e-06	5.11e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.95e-06	5.11e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—PIK3CA—liver cancer	8.89e-06	5.07e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—VEGFA—liver cancer	8.85e-06	5.05e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—HMOX1—liver cancer	8.84e-06	5.04e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CDKN1A—liver cancer	8.82e-06	5.03e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—liver cancer	8.82e-06	5.03e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MYC—liver cancer	8.82e-06	5.03e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TGFB1—liver cancer	8.8e-06	5.02e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—STAT3—liver cancer	8.76e-06	5e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—RAF1—liver cancer	8.75e-06	4.99e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—PIK3CA—liver cancer	8.75e-06	4.99e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—GSTM1—liver cancer	8.7e-06	4.96e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—RAF1—liver cancer	8.68e-06	4.95e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CYCS—liver cancer	8.68e-06	4.95e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—liver cancer	8.6e-06	4.91e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CD—liver cancer	8.57e-06	4.89e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PIK3CA—liver cancer	8.56e-06	4.88e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PIK3CA—liver cancer	8.56e-06	4.88e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CB—liver cancer	8.53e-06	4.87e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GGT1—liver cancer	8.52e-06	4.86e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GOT1—liver cancer	8.52e-06	4.86e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—MTHFR—liver cancer	8.51e-06	4.85e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—RAF1—liver cancer	8.5e-06	4.85e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—RAF1—liver cancer	8.5e-06	4.85e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MTOR—liver cancer	8.48e-06	4.84e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CB—liver cancer	8.48e-06	4.84e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—ALB—liver cancer	8.46e-06	4.83e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—HRAS—liver cancer	8.44e-06	4.81e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PPARA—liver cancer	8.35e-06	4.76e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CB—liver cancer	8.3e-06	4.73e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CB—liver cancer	8.3e-06	4.73e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MTOR—liver cancer	8.3e-06	4.73e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MTOR—liver cancer	8.3e-06	4.73e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CPT1B—liver cancer	8.26e-06	4.71e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GLUL—liver cancer	8.26e-06	4.71e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CYP1A1—liver cancer	8.25e-06	4.71e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GSTM1—liver cancer	8.23e-06	4.7e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—HRAS—liver cancer	8.23e-06	4.69e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GSTP1—liver cancer	8.21e-06	4.68e-05	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—AKT1—liver cancer	8.21e-06	4.68e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KRAS—liver cancer	8.15e-06	4.65e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MYC—liver cancer	8.14e-06	4.64e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TGFB1—liver cancer	8.12e-06	4.63e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—HMOX1—liver cancer	8.1e-06	4.62e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—HRAS—liver cancer	8.09e-06	4.62e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL6—liver cancer	8.07e-06	4.61e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NR1H4—liver cancer	7.97e-06	4.55e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CDKN1B—liver cancer	7.95e-06	4.54e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—HRAS—liver cancer	7.92e-06	4.52e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—HRAS—liver cancer	7.92e-06	4.52e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—STAT3—liver cancer	7.87e-06	4.49e-05	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—AKT1—liver cancer	7.87e-06	4.49e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTA3—liver cancer	7.83e-06	4.47e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CYP1A1—liver cancer	7.8e-06	4.45e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CASP3—liver cancer	7.8e-06	4.45e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CDKN1B—liver cancer	7.79e-06	4.44e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CDKN1B—liver cancer	7.79e-06	4.44e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL2—liver cancer	7.78e-06	4.44e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL6—liver cancer	7.75e-06	4.42e-05	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—AKT1—liver cancer	7.7e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—AKT1—liver cancer	7.7e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—MTHFR—liver cancer	7.69e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GSTP1—liver cancer	7.65e-06	4.36e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CASP3—liver cancer	7.63e-06	4.35e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CASP3—liver cancer	7.63e-06	4.35e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL2—liver cancer	7.62e-06	4.35e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL2—liver cancer	7.62e-06	4.35e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCND1—liver cancer	7.59e-06	4.33e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL6—liver cancer	7.58e-06	4.32e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL6—liver cancer	7.58e-06	4.32e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—JUN—liver cancer	7.57e-06	4.32e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—HMOX1—liver cancer	7.55e-06	4.3e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GSTM1—liver cancer	7.54e-06	4.3e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPARA—liver cancer	7.54e-06	4.3e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KRAS—liver cancer	7.52e-06	4.29e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CTNNB1—liver cancer	7.51e-06	4.29e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.5e-06	4.28e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PIK3CA—liver cancer	7.49e-06	4.27e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CB—liver cancer	7.47e-06	4.26e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—AKT1—liver cancer	7.45e-06	4.25e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCND1—liver cancer	7.43e-06	4.24e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCND1—liver cancer	7.43e-06	4.24e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—JUN—liver cancer	7.41e-06	4.23e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—JUN—liver cancer	7.41e-06	4.23e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MMP9—liver cancer	7.37e-06	4.2e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CTNNB1—liver cancer	7.36e-06	4.2e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CTNNB1—liver cancer	7.36e-06	4.2e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CDKN1A—liver cancer	7.34e-06	4.19e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MYC—liver cancer	7.32e-06	4.17e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—TGFB1—liver cancer	7.3e-06	4.16e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—MTHFR—liver cancer	7.28e-06	4.15e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—AKT1—liver cancer	7.26e-06	4.14e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—liver cancer	7.24e-06	4.13e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MMP9—liver cancer	7.21e-06	4.11e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MMP9—liver cancer	7.21e-06	4.11e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CDKN1A—liver cancer	7.19e-06	4.1e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CDKN1A—liver cancer	7.19e-06	4.1e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTA4—liver cancer	7.17e-06	4.09e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MAPK8—liver cancer	7.17e-06	4.09e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CYP1A1—liver cancer	7.15e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CG—liver cancer	7.15e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—AKT1—liver cancer	7.15e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPARA—liver cancer	7.14e-06	4.07e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GSTM1—liver cancer	7.03e-06	4.01e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MAPK8—liver cancer	7.01e-06	4e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MAPK8—liver cancer	7.01e-06	4e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7e-06	3.99e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—AKT1—liver cancer	6.99e-06	3.99e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—AKT1—liver cancer	6.99e-06	3.99e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTA2—liver cancer	6.98e-06	3.98e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—HRAS—liver cancer	6.93e-06	3.95e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PIK3CA—liver cancer	6.91e-06	3.94e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PPARG—liver cancer	6.9e-06	3.94e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.78e-06	3.87e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KRAS—liver cancer	6.76e-06	3.86e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTA1—liver cancer	6.74e-06	3.84e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—liver cancer	6.68e-06	3.81e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—MTHFR—liver cancer	6.67e-06	3.8e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CYP1A1—liver cancer	6.67e-06	3.8e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NAT2—liver cancer	6.66e-06	3.8e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL6—liver cancer	6.63e-06	3.78e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—VEGFA—liver cancer	6.62e-06	3.77e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—STAT3—liver cancer	6.55e-06	3.74e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPARA—liver cancer	6.54e-06	3.73e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—VEGFA—liver cancer	6.48e-06	3.69e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—VEGFA—liver cancer	6.48e-06	3.69e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CG—liver cancer	6.46e-06	3.69e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—STAT3—liver cancer	6.41e-06	3.66e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—STAT3—liver cancer	6.41e-06	3.66e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.41e-06	3.66e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.41e-06	3.65e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—HRAS—liver cancer	6.39e-06	3.65e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ALDOB—liver cancer	6.39e-06	3.64e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CD—liver cancer	6.28e-06	3.58e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPARG—liver cancer	6.24e-06	3.56e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—MTHFR—liver cancer	6.21e-06	3.54e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PIK3CA—liver cancer	6.21e-06	3.54e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ALB—liver cancer	6.2e-06	3.54e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL6—liver cancer	6.12e-06	3.49e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—AKT1—liver cancer	6.12e-06	3.49e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CG—liver cancer	6.11e-06	3.49e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPARA—liver cancer	6.1e-06	3.48e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CRABP1—liver cancer	6.09e-06	3.48e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MYC—liver cancer	6.09e-06	3.47e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TGFB1—liver cancer	6.07e-06	3.46e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MYC—liver cancer	5.96e-06	3.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MYC—liver cancer	5.96e-06	3.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TGFB1—liver cancer	5.94e-06	3.39e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TGFB1—liver cancer	5.94e-06	3.39e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPARG—liver cancer	5.9e-06	3.37e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HRAS—liver cancer	5.75e-06	3.28e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CD—liver cancer	5.68e-06	3.24e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—AKT1—liver cancer	5.65e-06	3.22e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KRAS—liver cancer	5.62e-06	3.21e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ALB—liver cancer	5.61e-06	3.2e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CG—liver cancer	5.6e-06	3.2e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KRAS—liver cancer	5.51e-06	3.14e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KRAS—liver cancer	5.51e-06	3.14e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—IL6—liver cancer	5.5e-06	3.14e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.49e-06	3.13e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CB—liver cancer	5.48e-06	3.12e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPARG—liver cancer	5.41e-06	3.08e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CD—liver cancer	5.37e-06	3.07e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—HPGDS—liver cancer	5.33e-06	3.04e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ALB—liver cancer	5.31e-06	3.03e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.29e-06	3.02e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CG—liver cancer	5.22e-06	2.98e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CA—liver cancer	5.2e-06	2.97e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CA—liver cancer	5.17e-06	2.95e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—AKT1—liver cancer	5.07e-06	2.89e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CA—liver cancer	5.06e-06	2.89e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CA—liver cancer	5.06e-06	2.89e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPARG—liver cancer	5.04e-06	2.87e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—liver cancer	5e-06	2.85e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CB—liver cancer	4.95e-06	2.82e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CD—liver cancer	4.92e-06	2.81e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—liver cancer	4.89e-06	2.79e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—liver cancer	4.89e-06	2.79e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ALB—liver cancer	4.86e-06	2.77e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.82e-06	2.75e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—HRAS—liver cancer	4.78e-06	2.73e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.76e-06	2.72e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PSMA4—liver cancer	4.75e-06	2.71e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PSMD10—liver cancer	4.75e-06	2.71e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CB—liver cancer	4.68e-06	2.67e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HRAS—liver cancer	4.68e-06	2.67e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HRAS—liver cancer	4.68e-06	2.67e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GOT2—liver cancer	4.62e-06	2.63e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CD—liver cancer	4.59e-06	2.62e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL6—liver cancer	4.58e-06	2.61e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CA—liver cancer	4.56e-06	2.6e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ALB—liver cancer	4.53e-06	2.58e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL6—liver cancer	4.48e-06	2.55e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL6—liver cancer	4.48e-06	2.55e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYP2E1—liver cancer	4.34e-06	2.48e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CB—liver cancer	4.29e-06	2.45e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—AKT1—liver cancer	4.25e-06	2.42e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—AKT1—liver cancer	4.22e-06	2.41e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.2e-06	2.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—AKT1—liver cancer	4.13e-06	2.36e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—AKT1—liver cancer	4.13e-06	2.36e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYCS—liver cancer	4.06e-06	2.32e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CB—liver cancer	4e-06	2.28e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GOT1—liver cancer	3.99e-06	2.27e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GGT1—liver cancer	3.99e-06	2.27e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—AKT1—liver cancer	3.72e-06	2.12e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTP1—liver cancer	3.58e-06	2.04e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—HMOX1—liver cancer	3.53e-06	2.01e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CA—liver cancer	3.34e-06	1.9e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTM1—liver cancer	3.29e-06	1.88e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYP1A1—liver cancer	3.12e-06	1.78e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CA—liver cancer	3.02e-06	1.72e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—MTHFR—liver cancer	2.91e-06	1.66e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CA—liver cancer	2.86e-06	1.63e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPARA—liver cancer	2.85e-06	1.63e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—AKT1—liver cancer	2.73e-06	1.56e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CA—liver cancer	2.62e-06	1.49e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.56e-06	1.46e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—AKT1—liver cancer	2.47e-06	1.41e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CG—liver cancer	2.44e-06	1.39e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CA—liver cancer	2.44e-06	1.39e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPARG—liver cancer	2.36e-06	1.34e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—AKT1—liver cancer	2.33e-06	1.33e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CD—liver cancer	2.15e-06	1.23e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—AKT1—liver cancer	2.14e-06	1.22e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ALB—liver cancer	2.12e-06	1.21e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—AKT1—liver cancer	1.99e-06	1.14e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CB—liver cancer	1.87e-06	1.07e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CA—liver cancer	1.14e-06	6.51e-06	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—AKT1—liver cancer	9.32e-07	5.32e-06	CbGpPWpGaD
